In a major breakthrough for breast cancer treatment, AstraZeneca and Daiichi Sankyo’s new drug Datroway has been shown to extend survival and slow disease progression in patients with advanced forms of the illness.
Results from a late-stage clinical trial involving 644 participants revealed that Datroway reduced the risk of disease progression or death by 43% compared to standard chemotherapy. The findings offer renewed hope for patients whose cancer has spread beyond the breast and who have limited treatment options.
Datroway is part of a new generation of targeted antibody-drug conjugates (ADCs) designed to deliver chemotherapy directly to cancer cells while sparing healthy tissue. This precision approach aims to improve effectiveness and reduce side effects often associated with traditional cancer treatments.
AstraZeneca and Daiichi Sankyo said the drug’s performance exceeded expectations, with researchers noting that patients experienced longer periods without disease worsening and, in some cases, improved overall survival rates.
Experts have hailed the results as a major step forward in the fight against metastatic breast cancer, one of the leading causes of cancer-related deaths among women worldwide. Further trials and regulatory reviews are expected to determine when Datroway could become widely available to patients.
About the Author
